Da: GreatBookPrices, Columbia, MD, U.S.A.
EUR 48,53
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: BargainBookStores, Grand Rapids, MI, U.S.A.
Hardback or Cased Book. Condizione: New. Headache Disorders: New Advances in Management and Treatment Strategies. Book.
Da: California Books, Miami, FL, U.S.A.
EUR 52,96
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: GreatBookPrices, Columbia, MD, U.S.A.
EUR 52,73
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Da: Rarewaves USA, OSWEGO, IL, U.S.A.
EUR 59,16
Quantità: Più di 20 disponibili
Aggiungi al carrelloPaperback. Condizione: New.
EUR 64,76
Quantità: Più di 20 disponibili
Aggiungi al carrelloHardback. Condizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 51,70
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 58,44
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
EUR 60,97
Quantità: Più di 20 disponibili
Aggiungi al carrelloHardback. Condizione: New.
Da: Rarewaves.com UK, London, Regno Unito
EUR 60,06
Quantità: Più di 20 disponibili
Aggiungi al carrelloPaperback. Condizione: New.
Da: PBShop.store US, Wood Dale, IL, U.S.A.
EUR 55,60
Quantità: Più di 20 disponibili
Aggiungi al carrelloHRD. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Da: PBShop.store UK, Fairford, GLOS, Regno Unito
EUR 51,71
Quantità: Più di 20 disponibili
Aggiungi al carrelloHRD. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Da: Majestic Books, Hounslow, Regno Unito
EUR 53,82
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. Print on Demand.
Da: Books Puddle, New York, NY, U.S.A.
Condizione: New. Print on Demand.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 53,99
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. PRINT ON DEMAND.
Da: CitiRetail, Stevenage, Regno Unito
EUR 58,78
Quantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: new. Hardcover. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 57,04
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans.
Da: preigu, Osnabrück, Germania
EUR 65,65
Quantità: 5 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Headache Disorders | New Advances in Management and Treatment Strategies | Buch | Englisch | 2025 | MDPI AG | EAN 9783725843473 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.